Zhejiang Huakang Pharmaceutical Co., Ltd.

SHSE:605077 Stock Report

Market Cap: CN¥4.8b

Zhejiang Huakang Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Zhejiang Huakang Pharmaceutical has been growing earnings at an average annual rate of 6.8%, while the Food industry saw earnings growing at 2.5% annually. Revenues have been growing at an average rate of 20.1% per year. Zhejiang Huakang Pharmaceutical's return on equity is 9%, and it has net margins of 10%.

Key information

6.8%

Earnings growth rate

-0.9%

EPS growth rate

Food Industry Growth7.2%
Revenue growth rate20.1%
Return on equity9.0%
Net Margin10.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Zhejiang Huakang Pharmaceutical's (SHSE:605077) Anemic Earnings Might Be Worse Than You Think

Nov 02
Zhejiang Huakang Pharmaceutical's (SHSE:605077) Anemic Earnings Might Be Worse Than You Think

We Think That There Are Some Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Beyond Its Promising Earnings

May 02
We Think That There Are Some Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Beyond Its Promising Earnings

Recent updates

Zhejiang Huakang Pharmaceutical's (SHSE:605077) Anemic Earnings Might Be Worse Than You Think

Nov 02
Zhejiang Huakang Pharmaceutical's (SHSE:605077) Anemic Earnings Might Be Worse Than You Think

Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) Earnings Are Not Doing Enough For Some Investors

Oct 14
Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) Earnings Are Not Doing Enough For Some Investors

Zhejiang Huakang Pharmaceutical (SHSE:605077) Will Want To Turn Around Its Return Trends

Sep 26
Zhejiang Huakang Pharmaceutical (SHSE:605077) Will Want To Turn Around Its Return Trends

Improved Earnings Required Before Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077) Shares Find Their Feet

Jul 02
Improved Earnings Required Before Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077) Shares Find Their Feet

Zhejiang Huakang Pharmaceutical (SHSE:605077) May Have Issues Allocating Its Capital

May 28
Zhejiang Huakang Pharmaceutical (SHSE:605077) May Have Issues Allocating Its Capital

We Think That There Are Some Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Beyond Its Promising Earnings

May 02
We Think That There Are Some Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Beyond Its Promising Earnings

Revenue & Expenses Breakdown

How Zhejiang Huakang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:605077 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,846284190123
30 Jun 242,773325161129
31 Mar 242,767361139136
31 Dec 232,783371128124
30 Sep 232,654339113124
30 Jun 232,619363122105
31 Mar 232,44535912097
31 Dec 222,200319114100
30 Sep 221,99430810896
30 Jun 221,81326394105
31 Mar 221,6712368890
31 Dec 211,5942378784
30 Sep 211,5192578985
30 Jun 211,3442378073
31 Mar 211,3112537473
31 Dec 201,3203076765
30 Sep 201,35029720394
31 Dec 191,51127016154
31 Dec 181,40019912644
31 Dec 179255611228
31 Dec 16763298922

Quality Earnings: 605077 has a high level of non-cash earnings.

Growing Profit Margin: 605077's current net profit margins (10%) are lower than last year (12.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 605077's earnings have grown by 6.8% per year over the past 5 years.

Accelerating Growth: 605077's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 605077 had negative earnings growth (-16.4%) over the past year, making it difficult to compare to the Food industry average (-5.8%).


Return on Equity

High ROE: 605077's Return on Equity (9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies